文献类型：期刊文献

英文题名：Polydopamine Nanoformulations Induced ICD and M1 Phenotype Macrophage Polarization for Enhanced TNBC Synergistic Photothermal Immunotherapy

作者：Geng, Siqi[1,2];Fang, Baoru[1,2];Wang, Ke[1,2];Wang, Fang[2,3];Zhou, Yiqing[2];Hou, Yike[4];Iqbal, M. Zubair[4];Chen, Yanping[1,2];Yu, Zhangsen[1,2]

机构：[1]Shaoxing Univ, Sch Life & Environm Sci, Shaoxing 312000, Zhejiang, Peoples R China;[2]Shaoxing Univ, Sch Med, Med Sci Res Ctr, Lab Nanomed, Shaoxing 312000, Zhejiang, Peoples R China;[3]Wenzhou Med Univ, Clin Med Coll 1, Wenzhou 325000, Zhejiang, Peoples R China;[4]Zhejiang Sci Tech Univ, Inst Smart Biomed Mat, Sch Mat Sci & Engn, Hangzhou 310018, Zhejiang, Peoples R China

年份：2024

外文期刊名：ACS APPLIED MATERIALS & INTERFACES

收录：SCI-EXPANDED(收录号：WOS:001343792500001)、、EI(收录号：20244417298436)、Scopus(收录号：2-s2.0-85207440787)、WOS

基金：This work was financially supported by the Zhejiang Provincial Natural Science Foundation (LTGY24H030003) project, the Science and Technology Plan in Shaoxing City (2022A14026), the Medical and Health Science and Technology Plan Project of Zhejiang Province (2024KY495), and the Medical and Health Science and Technology Plan Project of Shaoxing (2022KY075).

语种：英文

外文关键词：polydopamine; triple-negative breast cancer; synergistic photothermal immunotherapy; immunogenic celldeath; macrophage polarization

外文摘要：Photothermal therapy (PTT) is a promising technology that can achieve the thermal ablation of tumors and induce immunogenic cell death (ICD). However, relying solely on the antitumor immune responses caused by PTT-induced ICD is insufficient to suppress tumor metastasis and recurrence effectively. Fortunately, multifunctional nanoformulation-based synergistic photothermal immunotherapy can eliminate primary and metastatic tumors and inhibit tumor recurrence for a long time. Herein, we select polydopamine (PDA) nanoparticles to serve as the carrier for our nanomedicine as well as a potent photothermal agent and modulator of macrophage polarization. PDA nanoparticles are loaded with the insoluble immune adjuvant Imiquimod (R837) to construct PDA(R837) nanoformulations. These straightforward yet highly effective nanoformulations demonstrate excellent performance, allowing for successful triple-negative breast cancer (TNBC) treatment through synergistic photothermal immunotherapy. Moreover, experimental results showed that PDA(R837) implementation of PTT is effective in the thermal ablation of primary tumors while causing ICD and releasing R837, further promoting dendritic cell (DC) maturation and activating the systemic antitumor immune response. Furthermore, PDA(R837) nanoformulations inhibit tumor metastasis and recurrence and achieve M1 phenotype macrophage polarization, achieving long-term and excellent antitumor efficacy. Therefore, the structurally simple PDA(R837) nanoformulations provide cancer treatment and have excellent clinical translational application prospects.